Comorbidities and Risk Factors of Patients Diagnosed with CRC after Positive Fecal Test in Real Life
- PMID: 36428650
- PMCID: PMC9688580
- DOI: 10.3390/cancers14225557
Comorbidities and Risk Factors of Patients Diagnosed with CRC after Positive Fecal Test in Real Life
Abstract
(1) Background: Fecal occult blood test (FOBT) is the modality of choice in most countries for colorectal cancer (CRC) screening. We aimed to investigate the risk factors for CRC among patients with a positive FOBT in real life. (2) Methods: This was a retrospective study that included patients who tested positive for FOBT. Data regarding the comorbidities and laboratories were collected and compared between CRC and non-CRC groups. (3) Results: Positive FOBT was found among 45,500 (5.36%) subjects and CRC was found in 1502 (3.3%). CRC patients were older, age 62.7 ± 7.15 years compared with 59.33 ± 7.3 years (p < 0.001), and had significantly higher rates of hypertension (48.4% vs. 44.7%, p = 0.002), iron-deficiency anemia (20.6% vs. 16.4, p < 0.001), family history of CRC (7.3% vs. 5.1%, p < 0.001), and previous CRC (6.5% vs. 0.3%, p < 0.001). Lower levels of hemoglobin, iron, and ferritin were found in the CRC group. Age, family history of CRC, and previous CRC were found to be significant risk factors for diagnosis of CRC after positive FOBT with OR of 1.057, 1.4, and 15.9, respectively. (4) Conclusions: Iron-deficiency anemia, family history of CRC, previous colorectal cancer, and low hemoglobin, iron, and ferritin levels should direct physicians to give high priority to colonoscopy scheduling.
Keywords: colorectal cancer; fecal testing; risk factor; screening.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.Ont Health Technol Assess Ser. 2009;9(10):1-40. Epub 2009 Sep 1. Ont Health Technol Assess Ser. 2009. PMID: 23074514 Free PMC article.
-
[Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].Gastroenterol Hepatol. 2009 Oct;32(8):565-76. doi: 10.1016/j.gastrohep.2009.01.179. Epub 2009 Jul 3. Gastroenterol Hepatol. 2009. PMID: 19577340 Review. Spanish.
-
Immunological fecal occult blood test vs. serum ferritin for detection of colorectal neoplasia in high risk asymptomatic population.Rev Gastroenterol Mex. 2011 Jul-Sep;76(3):191-8. Rev Gastroenterol Mex. 2011. PMID: 22041307
-
Clinical impact of the immunochemical fecal occult blood test for colorectal cancer screening in Brazil.Ann Gastroenterol. 2017;30(4):442-445. doi: 10.20524/aog.2017.0151. Epub 2017 Apr 27. Ann Gastroenterol. 2017. PMID: 28655982 Free PMC article.
-
[Features of colorectal cancer with fecal-occult-blood tests--comparison with colorectal cancer with no screening].Gan To Kagaku Ryoho. 1998 Aug;25(10):1514-8. Gan To Kagaku Ryoho. 1998. PMID: 9725042 Review. Japanese.
Cited by
-
Utility of Stool-Based Tests for Colorectal Cancer Detection: A Comprehensive Review.Healthcare (Basel). 2024 Aug 18;12(16):1645. doi: 10.3390/healthcare12161645. Healthcare (Basel). 2024. PMID: 39201203 Free PMC article. Review.
References
-
- Wilson J.M.G., Jungner G. Principles and Practice of Screening for Disease. WHO; Geneva, Switzerland: 1968. [(accessed on 6 October 2022)]. Available online: http://www.who.int/bulletin/volumes/86/4/07-050112BP.pdf.
LinkOut - more resources
Full Text Sources